Search results
Results From The WOW.Com Content Network
The Nova 301 Trial is looking to recruit approximately 25,000 people globally to see if an investigational mRNA vaccine can protect people against the symptoms caused by the norovirus stomach bug.
The present paper discusses the nature, transmission route, clinical manifestations, immune response mechanism, and vaccine research of Norovirus. The objective of this review manuscript is to systematically gather, analyze, and summarize recent research and investigations on norovirus in order to enhance our understanding of its ...
Moderna, Inc. today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403.
mRNA-1403 is an mRNA vaccine in development to prevent moderate to severe acute gastroenteritis caused by norovirus. The vaccine candidate is a trivalent formulation containing mRNA that encodes for virus-like particles (VLPs) designed to protect against multiple norovirus genotypes.
In a post-hoc analysis, researchers found that vaccinated participants had twice the odds of having no acute gastroenteritis or a positive quantitative polymerase chain reaction (PCR) test for...
Researchers at the University of North Carolina believe that if a suitably broad norovirus vaccine is administered to children who are around six months old, the jab could then guide the...
The mRNA-LNP bivalent vaccine encoding the major capsid protein VP1 from GI.1 and GII.4 of human norovirus, generated high levels of neutralizing antibodies, robust cellular responses, and...
The first Phase 3 randomised clinical trial of an investigational mRNA norovirus vaccine will open across the UK within the next two weeks. Sponsored by Moderna, the trial evaluates the efficacy and safety of a norovirus vaccine called mRNA-1403.
There is currently no licensed vaccine for norovirus AGE, and many features of the virus and the human immune response to it have made vaccine development a challenge.
There is no approved vaccine against norovirus, which sickens approximately 21 million people in the United States each year, including the 15% of children under age 5 who contract norovirus annually. Approximately 3 million sets of parents are forced by this virus to miss work – approximately 2.2 days on average – to care for their children.